Comparative Pharmacology
Head-to-head clinical analysis: ESTAZOLAM versus KLONOPIN RAPIDLY DISINTEGRATING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTAZOLAM versus KLONOPIN RAPIDLY DISINTEGRATING.
ESTAZOLAM vs KLONOPIN RAPIDLY DISINTEGRATING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
1-2 mg orally at bedtime.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."